Condition: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Sponsor: Instituto do Cancer do Estado de São Paulo
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population
This description comes directly from the study's public registry record.
Camila MV Moniz, Doctor · + 55 11 3893-3925 · camila.venchiarutti@hc.fm.usp.br
Raelson Miranda, Doctor · + 55 11 3893-3566 · raelson.m@hc.fm.usp.br
Always discuss trial participation with your own doctor first.
| Hospital São Carlos | Fortaleza, Ceará, Brazil | Not Yet Recruiting |
| Hospital São Rafael | Salvador, Estado de Bahia, Brazil | Not Yet Recruiting |
| Hospital Santa Cruz | Curitiba, Paraná, Brazil | Not Yet Recruiting |
| IDOR Recife | Recife, Pernambuco, Brazil | Not Yet Recruiting |
| Instituto D'or de Pesquisa e Ensino | São Paulo, São Paulo, Brazil | Recruiting |
| Instituto do Câncer do Estado de São Paulo - ICESP | São Paulo, São Paulo, Brazil | Recruiting |
| DF Star | Brasília, Brazil | Not Yet Recruiting |
| Instituto D'Or de Pesquisa e Ensino | Rio de Janeiro, Brazil | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06638931